FAM83B Inhibitors

FAM83B inhibitors generally operate by attenuating vital cellular signaling pathways. Many target the EGFR signaling cascade; compounds such as Erlotinib, Gefitinib, Lapatinib, and Afatinib bind to the ATP-binding site of the EGFR tyrosine kinase, thereby reducing its activation. By doing so, these inhibitors can indirectly suppress FAM83B activity, as the protein functions downstream of EGFR. This method of action effectively disrupts the EGFR signaling pathway, leading to the indirect impairment of FAM83B.

Simultaneously, FAM83B inhibitors may target the PI3K/AKT signaling pathway, of which FAM83B is a part. Inhibitors such as PI-103, LY294002, Wortmannin, and GDC-0941 are potent PI3K inhibitors that reducing the activation of the PI3K/AKT pathway, thus indirectly inhibiting FAM83B. Additionally, AKT-specific inhibitors like MK-2206, AZD5363, Perifosine, and Triciribine operate by specifically inhibiting AKT, a key component of the PI3K/AKT pathway, indirectly leading to the functional inhibition of FAM83B.